Syros Pharmaceuticals (NASDAQ:SYRS) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report released on Thursday. The firm issued a sell rating on the stock.

SYRS has been the subject of several other research reports. Piper Sandler reaffirmed an “overweight” rating and set a $5.00 target price (down previously from $13.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, August 13th. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. HC Wainwright reissued a “neutral” rating and issued a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Syros Pharmaceuticals currently has an average rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Trading Up 12.8 %

Shares of SYRS stock opened at $0.29 on Thursday. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.25 and a quick ratio of 2.25. The firm has a market cap of $7.87 million, a PE ratio of -0.10 and a beta of 1.59. The company has a 50-day moving average of $1.85 and a two-hundred day moving average of $3.58. Syros Pharmaceuticals has a 1-year low of $0.18 and a 1-year high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same quarter in the previous year, the business posted ($1.35) EPS. On average, analysts predict that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Buying and Selling

In other Syros Pharmaceuticals news, CEO Conley Chee bought 50,000 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were acquired at an average cost of $1.51 per share, with a total value of $75,500.00. Following the acquisition, the chief executive officer now directly owns 72,504 shares of the company’s stock, valued at $109,481.04. The trade was a 222.18 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Jason Haas bought 35,363 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was acquired at an average cost of $1.55 per share, for a total transaction of $54,812.65. Following the completion of the acquisition, the chief financial officer now directly owns 59,915 shares in the company, valued at approximately $92,868.25. This trade represents a 144.03 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 130,707 shares of company stock worth $206,491 over the last 90 days. 12.26% of the stock is owned by insiders.

Hedge Funds Weigh In On Syros Pharmaceuticals

A number of institutional investors have recently modified their holdings of SYRS. GSA Capital Partners LLP acquired a new position in shares of Syros Pharmaceuticals in the 3rd quarter valued at $34,000. Virtu Financial LLC acquired a new position in shares of Syros Pharmaceuticals in the 1st quarter valued at $64,000. Acadian Asset Management LLC acquired a new position in shares of Syros Pharmaceuticals in the 1st quarter valued at $91,000. Certuity LLC acquired a new position in shares of Syros Pharmaceuticals in the 2nd quarter valued at $109,000. Finally, Kennedy Capital Management LLC acquired a new position in Syros Pharmaceuticals in the 1st quarter valued at $2,166,000. 91.47% of the stock is owned by institutional investors and hedge funds.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.